Rachael Nokes - 07 Oct 2025 Form 4 Insider Report for scPharmaceuticals Inc. (SCPH)

Reporting relationship: CFO and Treasurer
Issuer ticker: SCPH
Reported as of: 07 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Oct 2025, 16:30:10 UTC
Prior SEC filing: 12 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Rachael Nokes

Key filing fact

Rachael Nokes filed Form 4 for scPharmaceuticals Inc. (SCPH) on 07 Oct 2025.

Key facts

This page summarizes Rachael Nokes's Form 4 filing for scPharmaceuticals Inc. (SCPH).
6 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 07 Oct 2025, 16:30.

Change

Previous filing in this sequence was filed on 12 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001769138 Primary reporting owner

Nokes Rachael

Relationship: CFO and Treasurer
Address: C/O SCPHARMACEUTICALS INC., 25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON
Signature: /s/ Rachael Nokes
Signature date: 07 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SCPH transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -30,386
Change %: -19%
Price
Shares after: 125,675
Date: 07 Oct 2025
Ownership: Direct
Footnotes: F1, F2

SCPH transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -125,675
Change %: -100%
Price
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -132,670
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 132,670
Exercise price: $3.34
Footnotes: F4

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -54,700
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 54,700
Exercise price: $4.31
Footnotes: F4

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -6,426
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,426
Exercise price: $3.81
Footnotes: F4

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -13,850
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,850
Exercise price: $4.88
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Rachael Nokes is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash,

Footnote F2

(Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.

Footnote F3

Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each restricted stock unit award with respect to shares of Common Stock ("RSU Award") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, became fully vested and was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the number of shares underlying such RSU Award immediately prior to such cancellation multiplied by (B) $5.35 and (ii) one CVR in respect of each share subject to such RSU Award.

Footnote F4

Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.